Evidence map›Paper›PMID 31177627›Full record

ArticleActa physiologica (Oxford, England)2020

Angiotensin II inhibits P-glycoprotein in intestinal epithelial cells.

Anoop Kumar, Shubha Priyamvada, Vikas Soni, Arivarasu N Anbazhagan, Tarunmeet Gujral, Ravinder K Gill, Waddah A Alrefai, Pradeep K Dudeja, Seema Saksena

Open access · greenAbstract read
In one paragraph

Article in Acta physiologica (Oxford, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Anoop KumarDivision of Gastroenterology & Hepatology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois.
Shubha PriyamvadaDivision of Gastroenterology & Hepatology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois.
Vikas SoniDivision of Gastroenterology & Hepatology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois.
Arivarasu N AnbazhaganDivision of Gastroenterology & Hepatology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois.
Tarunmeet GujralDivision of Gastroenterology & Hepatology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois.
Ravinder K GillDivision of Gastroenterology & Hepatology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois.
Waddah A AlrefaiDivision of Gastroenterology & Hepatology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois.
Pradeep K DudejaDivision of Gastroenterology & Hepatology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois.ORCID 0000-0003-2252-7703
Seema SaksenaDivision of Gastroenterology & Hepatology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois.ORCID 0000-0002-2166-6317
University of Illinois Chicago · US

Funding

Intestinal Anion Transporters: Function and RegulationR01DK054016 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DUDEJA, PRADEEP K · 1998 to 2022
$7.0M
Transporter Trafficking Mechanisms in Infectious DiarrheaR01DK092441 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DUDEJA, PRADEEP K · 2011 to 2020
$3.0M
Intestinal 5-HT Transporter: A novel therapeutic target for GI disordersR01DK098170 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI GILL, RAVINDER K · 2014 to 2022
$3.0M
Probiotics:Potential Therapeutic Roles in DiarrheaR01DK081858 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DUDEJA, PRADEEP K · 2008 to 2017
$2.5M
Gut-liver crosstalk in bile-acid induced diarrheaR01DK109709 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ALREFAI, WADDAH A. · 2016 to 2019
$1.1M
Novel Role of DRA/SLC26A3 Downregulation in Gut Dysbiosis, Inflammation and InfectionR56DK092441 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DUDEJA, PRADEEP K · 2023 to 2023
$533k
BLRD Research Career Scientist Award ApplicationIK6BX005243 · VA · JESSE BROWN VA MEDICAL CENTER · PI ALREFAI, WADDAH A. · 2020 to 2025
–
A Novel Role of DRA in IBD PathogenesisIK2BX004719 · VA · JESSE BROWN VA MEDICAL CENTER · PI KUMAR, ANOOP · 2019 to 2023
–
Regulation of Intestinal Sodium Absorption in Health and DiseaseI01BX002867 · VA · JESSE BROWN VA MEDICAL CENTER · PI Seema Saksena · 2016 to 2026
–
Mechanisms of Regulation of Intestinal Cl Absorption in IBD Associated DiarrheaI01BX002011 · VA · JESSE BROWN VA MEDICAL CENTER · PI DUDEJA, PRADEEP K · 2013 to 2024
–
Regulation of Intestinal Bile Acid Absorption in Health and Cholesterol-Related DisordersI01BX000152 · VA · JESSE BROWN VA MEDICAL CENTER · PI Waddah A. Alrefai · 2009 to 2026
–
BLRD VA I01 BX000152BLRD VA I01 BX002011BLRD VA I01 BX002867BLRD VA IK2 BX004719BLRD VA IK6 BX005243NIDDK NIH HHS R01 DK054016NIDDK NIH HHS R01 DK081858NIDDK NIH HHS R01 DK092441NIDDK NIH HHS R01 DK098170NIDDK NIH HHS R01 DK109709NIDDK NIH HHS R56 DK092441
6 · The paper itself

Abstract

aimP-glycoprotein (Pgp/MDR1) plays a major role in intestinal homeostasis. Decrease in Pgp function and expression has been implicated in the pathogenesis of IBD. However, inhibitory mechanisms involved in the decrease of Pgp in inflammation are not fully understood. Angiotensin II (Ang II), a peptide hormone predominantly expressed in the epithelial cells of the crypt-villus junction of the intestine, has been shown to exert pro-inflammatory effects in the gut. It is increased in IBD patients and animals with experimental colitis. Whether Ang II directly influences Pgp is not known.

methodsPgp activity was measured as verapamil-sensitive

resultsAng II (10 nM) significantly inhibited Pgp activity at 60 minutes. Ang II-mediated effects on Pgp function were receptor-mediated as the Ang II receptor 1 (ATR1) antagonist, losartan, blocked Pgp inhibition. Ang II effects on Pgp activity appeared to be mediated via PI3 kinase, p38 MAPK and Akt signalling. Ang II-mediated inhibition of Pgp activity was associated with a decrease in the surface membrane expression of Pgp protein via decreased exocytosis and was found to be dependent on the Akt pathway. Short-term treatment of Ang II (2 mg/kg b.wt., 2 hours) to mice also decreased the membrane expression of Pgp protein levels in ileum and colon.

conclusionOur findings provide novel insights into the role of Ang II and ATR1 in decreasing Pgp expression in intestinal inflammation.

Indexed as

Angiotensin IIAnimalsATP Binding Cassette Transporter, Subfamily B, Member 1Caco-2 CellsDose-Response Relationship, DrugEpithelial CellsGene Expression RegulationHumansIntestinal MucosaMicep38 Mitogen-Activated Protein KinasesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2Angiotensin IIATP Binding Cassette Transporter, Subfamily B, Member 1p38 Mitogen-Activated Protein KinasesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2AktAng II receptor 1 (ATR1)intestineMDR1p38 MAPKPI3K

Identifiers

PMID31177627
PMCPMC6899205
OpenAlexW2948968329

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.